
PARIS, France June 1st, 2020, Vivet Therapeutics announced today that both the Food and Drug Administration

Vivet is very happy to share the March 2020

Vivet Announces Publication in Nature Communications of Preclinical Data from VTX-803

Paris, France and New York, US, March 20, 2019 – Vivet Therapeutics

PARIS, France June 12th, 2018, Vivet Therapeutics, a biotechnology company developing novel gene therapies for rare

PARIS, France September 28th, 2017, Vivet Therapeutics is proud to announce that it has been named by FierceBiotech as one of 2017's

PARIS, France September 26th, 2017, Vivet Therapeutics, announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet’s lead gene therapy product

In Europe, a disease is defined as rare when it affects fewer than one out of every 2,000 people. However, as many as 30 million people may suffer from one of the more than 6,000 existing rare diseases.